Allarity Therapeutics, Inc. announced that an abstract on the Company's proprietary DRP technology has been accepted for a poster presentation at the 2023 American Society of Clinical Oncology Annual Meeting. Researchers will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago. The poster shows the final data from a phase 2 study evaluating the ability of the DRP companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis, a targeted liposomal formulation of cisplatin.

Allarity conducted the study in collaboration with investigators at hospitals in Denmark, as well as its CRO Smerud Medical Research International AS. The LiPlaCis program is currently licensed to Chosa Oncology AB for further clinical development.